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Abstract
Background: Hypoxia is associated with resistance to chemotherapy and radiotherapy and is randomly distributed
within malignancies. Characterization of changes in intratumoral hypoxic regions is possible with specially
developed PET tracers such as 18F-fluoroazomycin arabinoside (18F-FAZA) while tumor metabolism can be
measured with 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG). The purpose of this study was to study the effects of
chemotherapy on 18F-FAZA and 18F-FDG uptake simultaneously in non-small-cell lung cancer (NSCLC) patients
Methods: At baseline and after the second chemotherapy cycle, both PET/CT with 18F-FDG and 18F-FAZA was
performed in seven patients with metastasized NSCLC. 18F-FAZA and 18F-FDG scans were aligned with deformable
image registration using Mirada DBx. The primary tumors were contoured, and on the 18F-FDG scan, volumes of
interest (VOI) were drawn using a 41 % adaptive threshold technique. Subsequently, the resulting VOI was
transferred to the 18F-FAZA scan. 18F-FAZA maximum tumor-to-background (T/Bgmax) ratio and the fractional
hypoxic volume (FHV) were assessed. Measurements were corrected for partial volume effects. Finally, a voxel-by-
voxel analysis of the primary tumor was performed to assess regional uptake differences.
Results: In the primary tumor of all seven patients, median 18F-FDG standard uptake value (SUVmax) decreased
significantly (p = 0.03). There was no significant decrease in 18F-FAZA uptake as measured with T/Bgmax (p = 0.24)
or the FHV (p = 0.35). Additionally, volumetric voxel-by-voxel analysis showed that low hypoxic tumors did not
significantly change in hypoxic status between baseline and two cycles of chemotherapy, whereas highly hypoxic
tumors did. Individualized volumetric voxel-by-voxel analysis revealed that hypoxia and metabolism were not
associated before and after 2 cycles of chemotherapy.
Conclusions: Tumor hypoxia and metabolism are independent dynamic events as measured by 18F-FAZA PET
and 18F-FDG PET, both prior to and after treatment with chemotherapy in NSCLC patients.
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Background
Hypoxia is considered an important feature of malignant
tumors with direct influence on the efficacy of chemo-
and radiotherapy. Hypoxia is unevenly distributed within
tumors, that can be related to an abnormal vasculature
and to an elevation in interstitial pressure associated
with tumor growth [1]. Hypoxic tumor cells are associ-
ated with more aggressive phenotypes and with resist-
ance to both chemo- and radiotherapy [2].
The gold standard in assessing tumor hypoxia is the po-
larographic Eppendorf electrode method. Unfortunately,
this technique is rather invasive, and therefore, it can only
be applied in well-accessible superficial tumors. It mea-
sures oxygen concentrations at the site of the electrode
only and therefore is not indicative for the whole tumor.
Consequently, multiple punctures are necessary to meas-
ure heterogeneity in oxygen distribution within a tumor.
These shortcomings may be overcome by using a non-
invasive technique such as PET radiotracers aimed at visu-
alizing and quantifying hypoxia. Different radiotracers
have been developed, most of them based on nitroimida-
zole compounds. The intracellular retention of these com-
pounds is based on the oxygen concentration with tissue
retention (in vitro) in hypoxic conditions observed up to
28 times normal uptake [3, 4]. Nitroimidazole tracers are
diffused through the cell membranes and then undergo
reduction to yield radical anions. Under normoxic condi-
tions, these radical anions are reoxidized and diffuse out
of the cell. However, in a hypoxic environment, re-
oxidation cannot occur and the radicals are irreversibly
bound to macromolecules, resulting in increasing tracer
accumulation under decreasing oxygen concentration.
The most widely used PET hypoxia tracer from this group
is 18F-fluoromisonidazole (18F-FMISO). Another tracer is
18F-fluoroazomycin arabinoside (18F-FAZA) [5–9], which
compared to 18F-FMISO has a more favorable signal-to-
noise ratio [6, 10].
Hypoxia and glucose metabolism are distinct meta-
bolic processes, yet it seems closely interlinked due to
the so called Warburg effect [11]. The Warburg effect
comes from the observation that cancer cells produce
energy using anaerobic glycolysis, instead of oxidative
phosphorylation at the cost of increased glucose uptake.
The link between hypoxia and glucose metabolism is
through the hypoxia inducible factor (HIF). The HIF
complex activates the transcription of multiple genes
that are necessary for the Warburg effect to occur [12].
Consistent HIF pathway activation in tumors is related
to the expression of two different receptors viz., GLUT-1
and GLUT-3 as well as regulation of enzymes in the
glycolytic pathway [13–15]. There is a clear relationship
between 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) up-
take and especially GLUT-1 and also with GLUT-3 ex-
pression [16]. This suggests an interdependency of both
processes, and consequently, 18F-FDG uptake could
function as a biomarker of hypoxia. Indeed, such a rela-
tionship has been shown [17]. However, a number of re-
cent publications failed to show a clear relation between
the two tracers [8, 18–20].
Traditionally, in most patient studies, measurement of
the maximum and/or mean standard uptake value (SUV)
or the tumor-to-background (T/Bg) mean ratio is used.
Despite their widespread use, they all have a drawback in
the sense that heterogeneity of tumor metabolism is ig-
nored. Alternatively, assessing localized treatment effects
in the individual tumor areas may be possible by using
volumetric voxel-by-voxel tumor analysis techniques.
Previously, our group studied the relationship between
18F-FAZA and 18F-FDG uptake in untreated patients
using volumetric analysis [18]. Chemotherapy is stand-
ard treatment in advanced non-small-cell lung cancer
(NSCLC), and the impact on hypoxia and metabolism
within individual tumor areas has not been adequately
addressed.
The purpose of this paper is therefore to study the rela-
tion between hypoxia and metabolism by a voxel-by-voxel
approach in a clinical setting with 18F-FDG and 18F-FAZA.
We compared this analysis with the traditionally mea-
sured SUVmax and T/Bg. As a model for this comparison,
we chose to use patients with advanced NSCLC.
Methods
Patients
Treatment-naive patients with advanced stage IV
NSCLC were selected. All patients underwent PET scans
with both 18F-FAZA and 18F-FDG at baseline and after
2 cycles of chemotherapy. The study was approved by
the Institutional Review Board of the University Medical
Center Groningen. All patients gave written informed
consent prior to study participation.
18F-FDG PET/CT
18F-FDG PET was performed on a Siemens Biograph
mCT 64. 18F-FDG images were reconstructed according
to EANM guidelines [21]. Blood samples were taken be-
fore tracer injection to confirm acceptable blood glucose
level (<11 mmol/l) after a minimal 4 h fasting period.
Patients were injected with 3 MBq/kg bodyweight 18F-
FDG intravenously. After 60 min, a scan was made from
the mid-thigh to the brain. Scan times per bed position
were dependent on patient weight: 1 min per bed pos-
ition if less than 60 kg, 2 min if between 60 and 90 kg,
and 3 min if above 90 kg [22]. PET data were recon-
structed as described previously [18].
SUVs were obtained by delineating the tumor volume
of interest (VOI) comprising the entire tumor volume
using the IMALYTICS Research Workstation (Philips
Technologie GmbH Innovative Technologie, Aachen,
Kerner et al. EJNMMI Research  (2016) 6:33 Page 2 of 8
Germany) on 18F-FDG PET/CT images. The primary
tumor area was selected and the VOI delineated using
the 41 % adaptive threshold technique as described by
Cheebsumon et al [23]. SUVs were normalized for blood
glucose levels in accordance with EANM guidelines [21].
If the tumor size in the shortest axis was smaller than
30 mm, the SUVmax was corrected for partial volume
based on historical data obtained with a NEMA phan-
tom [18]. PET tumor response was assessed according
to the 1999 EORTC recommendations [24]. The volume
for determination of the background activity was delin-
eated posterior of the sternum in the mediastinal fat tis-
sue using the low-dose CT. This volume was chosen in
order to avoid possible confounding by active tumor
within the lymph node, and confounding due to arthero-
sclerotic plaques within the great mediastinal vessels.
This background volume had to be at least 14 ml.
Contrast-enhanced CT was performed consecutively
in the same session on the Somatom CT which is part
of the mCT. Scan time was 8 s, craniocaudally at inspir-
ation. Effective mAs was 80 and 120 kV with the care
dose setting was used. Slice thickness was 0.5 mm, and
pitch was 1.4 with a rotation of 0.5 s. Patients were
injected with 55 ml of Iomeron contrast 350 mg/ml
(Bracco Imaging Deutschland GmbH, Konstanz,
Germany) at a speed of 2.5 ml/s. The tumor size of the
primary tumor and response was measured according to
RECIST 1.1 criteria [25].
The baseline scan was performed before any therapy
was given as part of the diagnostic workup. The scan
after 2 cycles of chemotherapy was performed within
2 days after the second cycle of chemotherapy.
18F-FAZA PET/CT
18F-FAZA PET scans were made on the same mCT ma-
chine as described previously [18]. Patients received
370 MBq 18F-FAZA intravenously. After 120 min, a scan
was made from the mid-thigh to the brain. The same
18F-FDG scan patient position and fixation system were
used in order to improve reproducibility. The baseline
scan was performed as soon as possible after inclusion
(median 2 days after 18F-FDG PET). The scan after 2 cy-
cles of chemotherapy was performed within 3 days after
the second cycle of chemotherapy to study the influence
of chemotherapy on the FAZA distribution in the pri-
mary tumor (median 1 day after 18F-FDG PET).
Deformable image registration
Deformable image registration was performed using
Mirada DBx Build 1.1.1.3 (64 bit) (Mirada Medical Ltd,
Oxford, UK). First, an automatic rigid registration was
performed, followed by a CT-based deformable registra-
tion. For each patient, the 18F-FDG and 18F-FAZA scans
obtained at baseline and after 2 cycles of chemotherapy
were registered and deformed. This resulted in four de-
formed images:
1. Between 18F-FDG and 18F-FAZA at baseline
2. Between 18F-FDG and 18F-FAZA after 2 cycles of
chemotherapy
3. Between 18F-FDG at baseline and after 2 cycles of
chemotherapy
4. Between the deformed 18F-FAZA at baseline
generated from step 1 and the unaltered 18F-FAZA
images after 2 cycles of chemotherapy
The registered and deformed images were then imported
back into the Imalytics system for further analysis.
Voxel-by-voxel analysis
After the registration and deformation of the images,
each voxel in a VOI of the 18F-FAZA images was nor-
malized to the mean background value (obtained from
corresponding VOIs posterior of the sternum) in order
to calculate a T/Bg. This enables a regional comparison
between 18F-FDG SUV (normalized to glucose) and 18F-
FAZA T/Bg. Partial volume correction was applied to
the T/Bg data using the same method as for the 18F-
FDG PET data.
For regional comparison between baseline and follow-
up scans, the tumor VOI delineated in the baseline 18F-
FDG was transferred to the 18F-FAZA after image regis-
tration as described previously. To guarantee the use of
operator-independent reproducible VOI, the tumor VOI
delineated on the baseline 18F-FDG images using an au-
tomated method was used on the baseline to follow up
scan comparison of 18F-FAZA. To assess the regional
comparison between the four different deformed images
with their respective reference images, the voxel-by-
voxel comparison capabilities of the propagated align al-
gorithm of the IMALYTICS Research Workstation was
used. The function of the propagated align algorithm
was previously described by our group [26].
The T/Bgmax as well as the fractional hypoxic tumor
volume (FHV) was calculated using the voxel-by-voxel
analysis data (18F-FDG to 18F-FAZA, if this data was not
available then 18F-FAZA to 18F-FAZA). The 18F-FAZA
T/Bgmax was corrected for PVE using the same tech-
nique as for the 18F-FDG SUVmax data. The FHV was
defined as the fraction of the tumor volume exceeding a
T/Bg ratio of 1.4. In previous studies by our group, the
cutoff of 1.4 was used to define hypoxia [18, 27].
Statistics
Pre- and post-chemotherapy 18F-FDG and 18F-FAZA
scans using the maximum uptake values were analyzed
with the Wilcoxon signed rank test. The voxel-by-voxel
relationship per patient between the 18F-FDG SUV and
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the 18F-FAZA T/Bg at baseline and after 2 cycles of
chemotherapy was calculated using simple linear regres-
sion. All calculations were performed using SPSS 22.0
(International Business Machines Corp, Armonk, NY,




Seven patients with advanced stage IV NSCLC were in-
cluded. Six patients had adenocarcinoma, and one had
large cell lung carcinoma. Patient details are given in
Table 1. Chemotherapy consisted of a platinum contain-
ing doublets. Partial response according to RECIST was
observed in one patient, stable disease in four patients,
and progressive disease in two patients.
Pre- and post-chemotherapy differences in 18F-FAZA and
18F-FDG uptake using traditional (max and mean uptake)
methods
18F-FDG uptake (SUVmax) between baseline and after 2 cy-
cles of chemotherapy decreased significantly (p = 0.03)
(Table 1). No differences in T/Bgmax (p = 0.24) or FHV (p =
0.35) were observed when comparing 18F-FAZA uptake at
baseline and after 2 cycles of chemotherapy.
Pre- and post-chemotherapy uptake analyzed voxel-by-voxel
In pre-chemotherapy in 4/7 patients, a weak relationship
between FAZA T/Bg and 18F-FDG SUV was observed
with R2 values between 0.12 and 0.30 (Fig. 1). After 2 cy-
cles chemotherapy, only in two patients, R2 was 0.24 and
0.33; in the other patients, no relationship was observed
between 18F-FDG SUV and 18F-FAZA T/Bg (Fig. 1). In
one patient, a very weak relationship between 18F-FAZA
T/Bg and 18F-FDG SUV persisted at baseline and after
2 cycles of chemotherapy (R2 = 0.14 and R2 = 0.33,
respectively).
In areas with low 18F-FAZA uptake at baseline, a de-
crease of 18F-FAZA responses were seen, perhaps partly
due to noise. In areas with high 18F-FAZA uptake, reox-
ygenation became evident after chemotherapy (Fig. 2a).
A more evenly distributed decrease of 18F-FDG activity
was observed after 2 cycles of chemotherapy (Fig. 2b).
Four different patterns of hypoxic uptake were visible:
hypoxic areas that remained hypoxic, hypoxic areas that
became normoxic after treatment, normoxic areas that
became hypoxic after treatment, and normoxic areas
that remained normoxic (Table 2).
Discussion
In this proof-of-concept study, we analyzed whether
hypoxia is associated with metabolism by the use of a
voxel-by-voxel technique and traditional maximum in-
tensity SUV and T/Bg calculations. Our results show
that the technique can be used in a clinical setting. Het-
erogeneity in 18F-FDG distribution could easily be
assessed and the effects of chemotherapy varied with the
metabolic status of the tumor.
Our study is novel because it is to our knowledge the
first study that used 18F-FAZA volumetric tumor ana-
lysis besides the traditional maximum intensity methods
to study the effects of chemotherapy alone on hypoxia in
NSCLC patients.
Hypoxia and metabolism: chemotherapeutic effects
The image analyses showed a very dynamic tumor
hypoxia and metabolism illustrating the tracer uptake
heterogeneity. Voxel-by-voxel analysis showed no associ-
ation or at best a very weak association between the two
tracers (R2 ≤ 0.33). After chemotherapy, the metabolic
activity decreased within tumor areas, but the hypoxic
reactions remained very dynamic. The distribution of
hypoxic areas changed in the primary tumor inde-
pendently of metabolism. Examination by volumetric
Table 1 Comparison of the effect of chemotherapy on the primary tumor measured with 18F-FAZA and 18F-FDG PET including
tumor response in non-small-cell lung cancer
Patient Age Sex 18F-FAZA (T/Bg ratio)a 18F-FDG (SUVmax)
b Fractional hypoxic volume CT scan
Baseline 2 cycles Baseline 2 cycles Baseline 2 cycles
1 56 F 7.1 5.0 32.5 24.2 96 % 100 % PD
2 43 M 3.0 2.0 15.4 2.1 98 % 9 % SD
3 45 F 4.4 3.3 27.3 18.2 95 % 95 % PD
4 52 F 7.7 7.7 5.8 c 100 % 97 % SD
5 48 F 2.9 2.6 7.2 5.9 63 % 30 % SD
6 61 M 6.7 4.7 15.8 4.4 100 % 100 % SD
7 62 F 3.3 5.4 8.9 6.0 58 % 100 % PR
PR partial response, SD stabile disease, PD progressive disease
aUptake for the whole primary tumor was corrected for partial volume effect. It was then divided by the mean of the background activity and this is tumor to
background (T/Bg) value
bUptake for the whole primary tumor, expressed in SUV, were corrected for partial volume effect
cDue to a dosimeter error, not usable for qualitative comparison
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voxel-by-voxel analysis revealed that tumor regions with
initial high 18F-FAZA uptake tended to have a larger de-
crease in the18F-FAZA uptake than regions with an initial
low 18F-FAZA uptake, whereas a random distribution
around the overall baseline activity was observed. With
traditional analytic methods, hypoxia was also not associ-
ated with metabolism [8, 18–20].
There are three factors explaining the lack of a rela-
tionship. Most importantly, the Warburg effect occurs
even in the abundant presence of oxygen [12]; thus, in-
creased 18F-FDG uptake indicative of the Warburg effect
does not necessarily reflect hypoxia. Secondly, 18F-FDG
uptake is not only related to tumor cell uptake but also
related to other characteristics which are involved with
poor prognosis. Busk et al. investigated with different
tumor models in mice the correlation between hypoxia
using pimonidazole staining and 18F-FDG uptake and
found a correlation with an r of 0.15 [28]. These uptake
characteristics include immune cells/inflammation, local
cell density, high relative glycolytic rates, and extracellu-
lar acidosis [29, 30]. Importantly, 18F-FDG is a nonspe-
cific tracer yet identifies complimentary factors related
to prognosis. The third item is that nitroimidazole com-
pounds cannot differentiate between chronic and acute
hypoxia. Acute (transient) hypoxia and chronic hypoxia
can both co-exist within the same tumor [31]. An in
Fig. 1 Per patient comparison of regional voxel distribution in the primary tumor of 18F-FAZA (T/Bg, vertical axis) versus 18F-FDG (SUV, horizontal
axis) at baseline and after 2 cycles of chemotherapy. The horizontal axis represents the 18F-FDG uptake in SUV. The vertical axis represents the
18F-FAZA uptake in tumor-to-background ratio. Blue represents voxel distribution assessed at baseline, while green represents voxel distribution
assessed after 2 cycles of chemotherapy. 18F-FDG data of patient 4 was not available after 2 cycles of chemotherapy
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vivo study by Lin et al. demonstrated that acute or
chronic hypoxia had differential effects on the distinct
HIF proteins (HIF-1α and HIF-2α) [32]. In addition,
tumors have areas of hypoxia/anoxia and normoxia,
yet part of the tumor is within variable intermediate
oxygen levels [33]. The different effects of acute and
chronic hypoxia on HIF proteins and subsequently on
GLUT-1 expression may provide an explanation why
hypoxia and metabolism, while closely interlinked, are
not necessarily simultaneously measurable. This ex-
plains why 18F-FDG alone is not capable of discrimin-
ating between hypoxic and non-hypoxic regions in
NSCLC and stresses the need for a specific hypoxia
identifying imaging agent.
Volumetric analysis
This study indicates that volumetric analysis may bring
more understanding of tumor biology than the other
routine techniques will do. Using co-registered and de-
formed 18F-FAZA besides 18F-FDG gives a more detailed
insight and understanding in the relationship between
hypoxia and glucose metabolism in NSCLC prior to and
after chemotherapy. The hypoxic/metabolic distribution
changes in a tumor are very variable in time and tumor
location. This observation may have practical implica-
tions. It may allow selection for individualized treatment.
An example is specific hypoxic radiotherapy in stage III
disease or selection for pre-sensitization with hypoxia
modifying agents during chemotherapy. Selecting pa-
tients for pre-sensitization may be important. Previously,
no benefit could be demonstrated in a phase 3 study in
unselected NSCLC of the addition of a hypoxia modify-
ing agent (nitroglycerine) to a bevacizumab containing
chemotherapy regimen [34]. On the other hand, a clear
benefit was observed of adding tirapazamine (as an hyp-
oxia modifying agent) to chemoradiotherapy in patients
with head and neck cancer that were hypoxic according
to 18F-FMISO PET [35]. But again, in a phase III trial
with unselected patients, tirapazamine did not improve
outcome [36].
Fig. 2 Difference between two cycles of chemotherapy and baseline was assessed for 18F-FAZA T/Bg (a) and 18F-FDG SUV (b) in the all primary
tumor voxels of seven (18F-FAZA) and six (18F-FDG) patients, respectively. a The vertical line in figure (a) denotes the hypoxic cutoff of 1.4 T/Bg.
Areas above 1.4 T/Bg are considered hypoxic. A decrease in 18F-FAZA activity can be seen as a result of treatment, yet this is not so clear
compared to 18F-FDG. The decrease in 18F-FAZA activity is, however, most pronounced in the most hypoxic areas. b Per patient, different cutoff
values are seen, due to the use of the 41 % adoptive threshold technique in selecting tumor areas. A clear decrease in 18F-FDG activity in almost
all tumor voxels as a result of treatment. Although the decrease is clear overall, the decrease is most pronounced in areas with initially the
highest 18F-FDG uptake
Table 2 Per patient percentage change between baseline and after 2 cycles of chemotherapy in tumor hypoxic status
Pt. ID. Normoxic area that remained
normoxic (%)
Normoxic area that became
hypoxic (%)
Hypoxic area that became
normoxic (%)
Hypoxic area that remained
hypoxic (%)
1. 0 0 0 100
2. <1 1 84 15
3. 0 0 18 82
4. 0 <1 3 97
5. 37 0 33 30
6. 0 0 <1 100
7. 1 41 2 56
Hypoxic/normoxic cutoff was defined as 1.4 T/Bg ratio
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Limitations of this study
In this study protocol, we used 3 min per bed position
in order to perform whole body imaging. This resulted
in adequate images. After including the first patients, we
started performing 15 min per bed position as well and
only performed thoracic imaging. Using 15 min per bed
position reduced signal noise and resulted in improved
images. Because we chose to perform whole body scans,
a 4D mode to compensate for breathing motion could
not be used. However, the extent of breathing motion in
our study was minimal; as in 5/7 patients, the primary
tumor was located in the upper and middle lobe, re-
spectively, and one patient had a metastasis of the clav-
icle only.
Although 18F-FMISO is studied most often, we used
18F-FAZA. 18F-FAZA shows superior biokinetics com-
pared to 18F-FMISO [6, 10]. In addition, 18F-FMISO is
more lipophilic and is cleared primarily via the hepato-
biliary tract, while 18F-FAZA is mainly excreted renal,
thereby giving less background noise to the scans [37].
However, as equally the case with all other hypoxic PET
tracers, the 18F-FAZA images are more difficult to inter-
pret then 18F-FDG due to the lower contrast with nor-
mal tissue.
Volumetric tumor analysis, although promising, has
some limitations. Most importantly, the accuracy is
dependent on good co-registration with the CT and on
minimal tumor size changes. The use of this method will
introduce variability within the measured values. At
present, it is not clear whether this variability introduces
clinically significant errors within the measurement. Nor
is it known whether further fine-tuning of the software
settings will limit the variability.
A concern inherent to the use of PET to study hypoxia
is the resolution. The voxel size can be larger than the
hypoxic area (especially when there is a combination of
severe hypoxia and necrosis), and subsequently, such
small hypoxic hotspots can potentially be classified as
normoxic if the average value of the particular voxel is
below the hypoxic cutoff value, and so leading to a false
negative result [38].
Conclusions
Different metabolic features of NSCLC are measured by
18F-FDG and 18F-FAZA. As measured with 18F-FAZA
and 18F-FDG, tumor hypoxia is a dynamic phenomenon
not associated with tumor metabolism, either before or
after treatment in NSCLC patients with chemotherapy.
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